UnitedHealth Group is in focus ahead of its upcoming Q2 results after raising earnings guidance, tightening cost controls, and benefiting from higher Medicare Advantage plan rates. The most followed narrative on the stock pegs its fair value at $395, which is 9.3% below the last close of $431.68, suggesting the shares are overvalued. The market is currently valuing UnitedHealth through the narrow lens of a traditional insurer struggling with Medicare Advantage rate cuts and CMS regulatory headwinds for 2027, while the thesis centers on the massive value of Optum that the market is discounting. The current P/E of 32.5x sits between the US Healthcare industry average of 25x and a peer average of 39.6x, with a fair ratio of 42.6x implying potential upside before the stock looks stretched. Key risks include further tightening of CMS policy on Medicare Advantage or execution stumbles at Optum.
UnitedHealth Group IncorporatedArticle flags stock as 9.3% overvalued based on fair value estimate of $395, suggesting downside risk ahead of Q2 results.